Guardian Pharmacy Services, Inc.
NYSE:GRDN · New York Stock Exchange
+$0.17 today
Vol 0.48M · Avg 0.48M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NYSE:GRDN · Revenue to Net Income
Key Ratios
Analysis
$1.5B of revenue converted into $53.1M of net income for the selected period. Gross margin is 20.9% and net margin is 3.6%, showing how much revenue survives after costs and taxes. EPS is $0.83, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B +17.9% | $1.2B +17.4% | $1.0B +15.1% | $908.9M +14.8% | $792.1M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $1.2B +18.6% | $984.0M +17.4% | $837.9M +15.9% | $723.0M +14.6% | $630.8M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $282.0M +15.4% | $244.4M +17.3% | $208.3M +12.1% | $185.9M +15.3% | $161.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 19.5% -0.4pp | 19.9% -0.0pp | 19.9% -0.5pp | 20.4% +0.1pp | 20.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $0 | $0 | $0 | $0 | $0 | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $193.1M -37.2% | $307.3M +83.6% | $167.4M +25.0% | $133.9M +2.1% | $131.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $193.1M -37.2% | $307.3M +83.6% | $167.4M +25.0% | $133.9M +2.1% | $131.1M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $22.3M +13.0% | $19.8M +8.4% | $18.2M +10.1% | $16.6M +0.2% | $16.5M | $374.2M | $1.2B | $631.8M |
| EBITDA | $96.4M +322.0% | -$43.4M -173.8% | $58.8M -13.7% | $68.2M +46.6% | $46.5M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 6.7% +10.2pp | -3.5% -9.2pp | 5.6% -1.9pp | 7.5% +1.6pp | 5.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | $88.9M +241.3% | -$62.9M -253.7% | $40.9M -21.2% | $52.0M +72.4% | $30.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 6.1% +11.3pp | -5.1% -9.0pp | 3.9% -1.8pp | 5.7% +1.9pp | 3.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $665.0K -79.7% | $3.3M +14.7% | $2.9M +48.4% | $1.9M +17.7% | $1.6M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$15.5M -335.5% | -$3.6M -10.3% | -$3.2M -38.5% | -$2.3M -27.7% | -$1.8M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $73.4M +210.4% | -$66.5M -276.2% | $37.7M -24.0% | $49.7M +75.3% | $28.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 5.1% +10.5pp | -5.4% -9.0pp | 3.6% -1.9pp | 5.5% +1.9pp | 3.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $24.5M +437.0% | $4.6M | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | $49.2M +156.4% | -$87.3M -465.2% | $23.9M -32.5% | $35.4M +117.1% | $16.3M | $4.9B | $4.8B | $4.7B |
| Net Margin | 3.4% +10.5pp | -7.1% -9.4pp | 2.3% -1.6pp | 3.9% +1.8pp | 2.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $1 +144.6% | -$2 -553.8% | $0 -32.8% | $1 +114.8% | $0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $1 +144.1% | -$2 -553.8% | $0 -32.8% | $1 +114.8% | $0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $62.4M +0.6% | $62.0M +1.9% | $60.8M +0.0% | $60.8M +0.0% | $60.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $63.3M +2.1% | $62.0M +1.9% | $60.8M +0.0% | $60.8M +0.0% | $60.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Twist Bioscience Corporation
NASDAQ:TWST
$5.36B
10x Genomics, Inc.
NASDAQ:TXG
$4.44B
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
$3.83B
National HealthCare Corporation
AMEX:NHC
$3.00B
Nuvation Bio Inc.
NYSE:NUVB
$1.89B
Pediatrix Medical Group, Inc.
NYSE:MD
$1.89B
Mesoblast Limited
NASDAQ:MESO
$1.84B
PROCEPT BioRobotics Corporation
NASDAQ:PRCT
$1.22B
QuidelOrtho Corporation
NASDAQ:QDEL
$901.48M
Janux Therapeutics, Inc.
NASDAQ:JANX
$851.95M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does GRDN generate?
Guardian Pharmacy Services, Inc. (GRDN) reported $1.45B of revenue in fiscal 2025.
Is GRDN profitable?
Guardian Pharmacy Services, Inc. (GRDN) reported $49.22M of net income, with a net margin of 3.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.